The risk factor for adverse pregnancy outcomes and its impact on clinical effect in IgA nephropathy: A retrospective observational study

Fengxia Zhang,Zhiyong Xie,Siqi Peng,Nan Jiang,Bohou Li,Boxi Chen,Shuting Deng,Ye Yuan,Qiong Wu,Sichun Wen,Yiming Tao,Jianchao Ma,Sijia Li,Ting Lin,Feng Wen,Zhuo Li,Renwei Huang,Zhonglin Feng,Chaosheng He,Wenjian Wang,Xinling Liang,Lixia Xu,Yue Shen,Niechao Hong,Ruiquan Xu,Shuangxin Liu
DOI: https://doi.org/10.1111/nep.14387
2024-09-11
Nephrology
Abstract:Summary at a Glance Pregnant IgA nephropathy (IgAN) patients with anaemia and higher IgM levels had higher risk for adverse pregnancy outcomes (APO). IgAN pregnant women with APO would be harder to achieve proteinuria remission, deserving further aggressive therapy as early as possible. Aim IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Pregnant IgAN patients are more susceptible to adverse pregnancy outcomes (APO). However, the risk factor for APO and its effects on the long‐term renal outcome of pregnant IgAN patients remained unclear. Methods We performed a retrospective observational study covering 2003–2019 that included 44 female IgAN patients with pregnancy history to investigate the risk factor for APO and its impact on clinical outcome in IgAN. Renal function outcome and proteinuria remission were evaluated in pregnant IgAN women with and without APO. Results In this retrospective and observational study, we found that patients with APO exhibited higher levels of serum creatinine and IgM, and lower haemoglobin levels while other clinical characteristics, pathological characteristics and therapy protocol had no significant difference. We found that anaemia and a higher level of serum IgM were independent risk factors for APO. IgAN pregnant women without APO experienced a higher proportion of proteinuria remission than those with APO, but there is no difference in the renal function outcome. Conclusion Pregnant IgAN patients with higher risks, including lower haemoglobin levels and higher IgM levels deserve intensive monitoring, and aggressive therapy to reduce proteinuria should be carried out in pregnant IgAN patients with APO.
urology & nephrology
What problem does this paper attempt to address?